Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
ГлавнаяРезультаты поиска
СтатьяИскать документыПерейти к записи. 2019; № 15: 38–49. DOI:10.21518/2079-701X-2019-15-38-49
Место омализумаба в терапии аллергических заболеваний
Искать документыПерейти к записи[1]
Искать документыПерейти к записи[1]
Аффилированные организации
[1]Искать документыПерейти к записи
Аннотация
В статье описан современный подход к применению антиIgE-терапии при аллергической бронхиальной астме и сопутствующих этому заболеванию состояниях. Гуманизированное моноклональное антитело против IgE, препарат омализумаб (Ксолар®) – это перспективный способ лечения IgE-опосредованных аллергических заболеваний. Получены многочисленные доказательства эффективности омализумаба при аллергической бронхиальной астме и хронической спонтанной (идиопатической) крапивнице, на основании которых проведены глобальные метаанализы, подтвердившие эффективность и безопасность этой терапевтической стратегии. В последних научных статьях активно обсуждается возможность расширения показаний для медицинского применения омализумаба. Опубликованы результаты клинических исследований эффективности и безопасности использования омализумаба при аллергическом рините, аллергическом кератоконъюнктивите, хроническом риносинусите, назальных полипах, хронической идиопатической крапивнице, пищевой аллергии, при аллергенспецифической иммунотерапии, атопическом дерматите, аллергическом бронхолегочном аспергиллезе – в случаях коморбидности с бронхиальной астмой. Наиболее изучен и доказан клинический эффект омализумаба у пациентов с аллергической бронхиальной астмой. В настоящий момент ряд клинических исследований оценивают отдаленные результаты длительного применения омализумаба или состояние после его отмены у пациентов с аллергической бронхиальной астмой и различными коморбидностями.
Ключевые слова
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Рубрики Mesh
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Литература

Warner J.O., Kaliner M.A., Crisci C.D., Del Giacco S., Frew A.J., Liu G.H., et al. Allergy practice worldwide: a report by the World Allergy Organization Specialty and Training Council. Int Arch Allergy Immunol. 2006;139:166–74. doi: 10.1159/000090502..
DOI: 10.1159/000090502

Weinberg E.G. The WAO white book on allergy 2011-2012: review article. Curr Allergy Clin Immunol. 2011;24(3):156–7.

Pawankar R.C.G., Holgate S.T. World allergy organization (WAO) white book on allergy. Update. 2013;248. doi: 10.1186/1939-4551-6-3..
DOI: 10.1186/1939-4551-6-3

Nitin J., Palagani R., Shradha N.H., Vaibhav J., Kowshik K., Manoharan R., et al. Prevalence, severity and risk factors of allergic disorders among people in south India. Afr Health Sci. 2016;16:201–209. doi: 10.4314/ahs.v16i1.27..
DOI: 10.4314/ahs.v16i1.27

Hannah J., Gould H.J., Sutton B.J. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8:205-217. doi: 10.1038/nri2273..
DOI: 10.1038/nri2273

Siracusa M.C., Kim B.S., Spergel J.M., Artis D. Basophils and allergic inflammation. J Allergy Clin Immunol. 2013;132:789-801. doi: 10.1016/j.jaci.2013.07.046..
DOI: 10.1016/j.jaci.2013.07.046

Cameron L., Christodoulopoulos P., Lavigne F., Nakamura Y., Eidelman D., McEuen A., et al. Evidence for local eosinophil differentiation within allergic nasal mucosa: inhibition with soluble IL-5 receptor. J Immunol. 2000;164:1538-1545. doi: 10.4049/jimmunol.164.3.1538..
DOI: 10.4049/jimmunol.164.3.1538

Muramatsu M., Kinoshita K., Fagarasan S., Yamada S., Shinkai Y., Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102:553-563. doi: 10.1016/s0092-8674(00)00078-7..
DOI: 10.1016/s0092-8674(00)00078-7

Pène J., Rousset F., Brière F., Chrétien I., Bonnefoy J.Y., Spits H., et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc Natl Acad Sci U S A. 1988;85:6880-6884. doi: 10.1073/pnas.85.18.6880..
DOI: 10.1073/pnas.85.18.6880

Luger E.O., Fokuhl V., Wegmann M., Abram M., Tillack K., Achatz G., et al. Induction of longlived allergen-specific plasma cells by mucosal allergen challenge. J Allergy Clin Immunol. 2009;124:819-826.e4. doi: 10.1016/j.jaci.2009.06.047..
DOI: 10.1016/j.jaci.2009.06.047

Erazo A., Kutchukhidze N., Leung M., Christ A.P., Urban J.F. Jr, Curotto de Lafaille M.A., et al. Unique maturation program of the IgE response in vivo. Immunity. 2007;26:191-203. doi: 10.1016/j.immuni.2006.12.006..
DOI: 10.1016/j.immuni.2006.12.006

Suh K.S., Park H.S., Nahm D.H., Kim Y.K., Lee Y.M., Park K. Role of IgG, IgA, and IgE antibodies in nasal polyp tissue: their relationships with eosinophilic infiltration and degranulation. J Korean Med Sci. 2002;17:375-380. doi: 10.3346/jkms.2002.17.3.375..
DOI: 10.3346/jkms.2002.17.3.375

Sheahan P., Ahn C.N., Harvey R.J., Wise S.K., Mulligan R.M., Lathers D.M., et al. Local IgE production in nonatopic nasal polyposis. J Otolaryngol Head Neck Surg. 2010;39(1):45-51. Available at: https://europepmc.org/abstract/med/20122344.https://europepmc.org/abstract/med/20122344

Sheahan P., Ahn C.N., Harvey R.J., Wise S.K., Mulligan R.M., Lathers D.M., et al. Local IgE production in nonatopic nasal polyposis. J Otolaryngol Head Neck Surg. 2010;39(1):45-51. Available at: https://europepmc.org/abstract/med/20122344.https://europepmc.org/abstract/med/20122344

Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151(5):2623– 2632. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8360482.https://www.ncbi.nlm.nih.gov/pubmed/8360482

Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151(5):2623– 2632. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8360482.https://www.ncbi.nlm.nih.gov/pubmed/8360482

Corren J., Busse W., Meltzer E.O., Mansfield L., Bensch G., Fahrenholz J., et al. A randomized, controlled, phase 2 study of AMG 317, an IL4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med. 2010;181:788-96. doi: 10.1164/rccm.200909-1448oc..
DOI: 10.1164/rccm.200909-1448oc

Incorvaia C., Mauro M., Riario-Sforza G.G., Frati F., Tarantini F., Caserini M. Current and future applications of the anti-IgE antibody omalizumab. Biologics. 2008;2(1):67–73. doi: 10.2147/btt.s1800..
DOI: 10.2147/btt.s1800

Wenzel S., Ford L., Pearlman D., Spector S., Sher L., Skobieranda F., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455-66. doi: 10.1056/nejmoa1304048..
DOI: 10.1056/nejmoa1304048

Kimura S., Pawankar R., Mori S., Nonaka M., Masuno S., Yagi T., et al. Increased expression and role of thymic stromal lymphopoietin in nasal polyposis. Allergy Asthma Immunol Res. 2011;3:186-93. doi: 10.4168/aair.2011.3.3.186..
DOI: 10.4168/aair.2011.3.3.186

Gauvreau G.M., O’Byrne P.M., Boulet L.P., Wang Y., Cockcroft D., Bigler J., et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370:2102-2110. doi: 10.1056/nejmoa1402895..
DOI: 10.1056/nejmoa1402895

Zheng L., Li B., Qian W., Zhao L., Cao Z., Shi S., et al. Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab. Biochem Biophys Res Commun. 2008;375:619–622. doi: 10.1016/j.bbrc.2008.08.055..
DOI: 10.1016/j.bbrc.2008.08.055

Eggel A., Baravalle G., Hobi G., Kim B., Buschor P., Forrer P., et al. Accelerated dissociation of IgE-FcepsilonRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. J Allergy Clin Immunol. 2014;133:1709–19 e1708. doi: 10.1016/j.jaci.2014.02.005..
DOI: 10.1016/j.jaci.2014.02.005

Chang T.W., Wu P.C., Hsu C.L., Hung A.F. AntiIgE antibodies for the treatment of IgEmediated allergic diseases. Adv Immunol. 2007;93:63–119. doi: 10.1016/s0065-2776(06)93002-8..
DOI: 10.1016/s0065-2776(06)93002-8

Holgate S., Bousquet J., Wenzel S., Fox H., Liu J., Castellsague J. Efficacy of omalizumab, all anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthmarelated morbidity and mortality. Curt Med Res Opin. 2001;17(4):233–40. doi: 10.1185/030079901753403126..
DOI: 10.1185/030079901753403126

Zhou B., Lin B., Li J., Qian W., Hou S., Zhang D., et al. Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects. mAbs. 2012;4:110–19. doi: 10.4161/mabs.4.1.18349..
DOI: 10.4161/mabs.4.1.18349

Kawakami T., Blank U. From IgE to omalizumab. J Immunol. 2016;197:4187–4192. doi: 10.4049/jimmunol.1601476..
DOI: 10.4049/jimmunol.1601476

Tonacci A., Billeci L., Pioggia G., Navarra M., Gangemi S. Omalizumab for the treatment of chronic idiopathic urticaria: systematic review of the literature. Pharmacotherapy. 2017;37:464–480. doi: 10.1002/phar.1915..
DOI: 10.1002/phar.1915

Lustgarten J., Eshhar Z. Specific elimination of Ige production using T-cell lines expressing chimeric T-cell receptor genes. Eur J Immunol. 1995;25:2985–2991. doi: 10.1002/eji.1830251041..
DOI: 10.1002/eji.1830251041

Jardieu P.M., Fick R.B. IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol. 1999;118(2–4):112–115. doi: 10.1159/000024043..
DOI: 10.1159/000024043

Holgate S., Casale T., Wenzel S., Bousquet J., Deniz Y., Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115:459-465. doi: 10.1016/j.jaci.2004.11.053..
DOI: 10.1016/j.jaci.2004.11.053

Cox L., Platts-Mills T.A., Finegold I., et al; American Academy of Allergy, Asthma & Immunology; American College of Allergy, Asthma and Immunology. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120(6):1373–1377. doi: 10.1016/j.jaci.2007.09.032..
DOI: 10.1016/j.jaci.2007.09.032

Nopp A., Johansson S.G., Adédoyin J., Ankerst J., Palmqvist M., Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy. 2010;65(1):56–60. doi: 10.1111/j.1398-9995.2009.02144.x..
DOI: 10.1111/j.1398-9995.2009.02144.x

Ledford D., Busse W., Trzaskoma B., et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140(1):162– 169.e2. doi: 10.1016/j.jaci.2016.08.054..
DOI: 10.1016/j.jaci.2016.08.054

Domingo C., Pomares X., Navarro A., et al. A step-down protocol for treatment in oral corticosteroid dependent allergic asthma patients. Br J Clin Pharmacol. 2018;84(2):339– 348. doi: 10.1111/bcp.13453..
DOI: 10.1111/bcp.13453

Vennera Mdel C., Valero A., Uria E., Forne C., Picado C. Cost-effectiveness analysis of omalizumab for the treatment of severe persistent asthma in real clinical practice in Spain. Clin Drug Investig. 2016;36(7):567–578. doi: 10.1007/s40261-016-0402-2..
DOI: 10.1007/s40261-016-0402-2

Suzuki C., Lopes da Silva N., Kumar P., Pathak P., Ong S.H. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. J Med Econ. 2017;20(8):832–839. doi: 10.1080/13696998.2017.1333513..
DOI: 10.1080/13696998.2017.1333513

Zafari Z., Sadatsafavi M., Mark FitzGerald J.; Canadian Respiratory Research Network. Canadian Respiratory Research Network. Costeffectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. Cost Eff Resour Alloc. 2018;30:16–3. doi: 10.1186/s12962-018-0089-8..
DOI: 10.1186/s12962-018-0089-8

Global Initiative for Asthma Report, Global strategy for Asthma Management and Prevention. Available at: https://ginasthma. org/2018-gina-report-global-strategy-forasthma-management-and-prevention/ Accessed May 13, 2018.https://ginasthma

Global Initiative for Asthma Report, Global strategy for Asthma Management and Prevention. Available at: https://ginasthma. org/2018-gina-report-global-strategy-forasthma-management-and-prevention/ Accessed May 13, 2018.https://ginasthma

Zafari Z., Sadatsafavi M., Marra C.A., Chen W., FitzGerald J.M. Cost-Effectiveness of bronchial thermoplasty, omalizumab, and standard therapy for moderate-to-severe allergic asthma. PLoS One. 2016;11(1):e0146003. doi: 10.1371/journal.pone.0146003..
DOI: 10.1371/journal.pone.0146003

Tatar M., Sezen S., Senturk A., Balp M.M., Saylan M., Keskinaslan A. Costeffectiveness of omalizumab in chronic idiopathic urticarial refractory to H1-antihistamines in Turkey. Value Health. 2014;17(7):A604. doi: 10.1016/j.jval.2014.08.2101..
DOI: 10.1016/j.jval.2014.08.2101

Alhossan A., Lee C.S., MacDonald K., Abraham I. «Real-life» Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. J Allergy Clin Immunol Pract. 2017;5(5):1362–1370.e2. doi: 10.1016/j.jaip.2017.02.002..
DOI: 10.1016/j.jaip.2017.02.002

Lai T., Wang S., Xu Z. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015;3(5):8191. doi: 10.1038/srep08191..
DOI: 10.1038/srep08191

Walker S., Monteil M., Phelan K., Lasserson T.J., Walters E.H. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006;19(2):CD003559. doi: 10.1002/14651858.cd003559.pub3..
DOI: 10.1002/14651858.cd003559.pub3

Siergiejko Z., Świebocka E., Smith N., et al. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Curr Med Res Opin. 2011;27(11):2223–2228. doi: 10.1185/03007995.2011.620950..
DOI: 10.1185/03007995.2011.620950

Domingo C., Moreno A., Jose Amengual M., Montуn C., Suбrez D., Pomares X. Omalizumab in the management of oral corticosteroiddependent IGE-mediated asthma patients. Curr Med Res Opin. 2011;27(1):45–53. doi: 10.1185/03007995.2010.536208..
DOI: 10.1185/03007995.2010.536208

Barnes N., Menzies-Gow A., Mansur A.H., et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma. 2013;50(5):529–536. doi: 10.3109/02770903.2013.790419..
DOI: 10.3109/02770903.2013.790419

Braunstahl G.J., Chen C.W., Maykut R., Georgiou P., Peachey G., Bruce J. The eXpeRience registry: the «real-world» effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141–1151. doi: 10.1016/j.rmed.2013.04.017..
DOI: 10.1016/j.rmed.2013.04.017

Normansell R., Walker S., Milan S.J., Walters E.H., Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):CD003559. doi: 10.1002/14651858. cd003559.pub4..
DOI: 10.1002/14651858. cd003559.pub4

Cardet J.C., Casale Т.В. New insights into the utility of omalizumab. J Allergy Clin Immunol. 2019;143(3):923-936. doi: 10.1016/j.jaci.2019.01.016..
DOI: 10.1016/j.jaci.2019.01.016

Zhao Z.-T. et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742-1750. doi: 10.1016/j.jaci.2015.12.1342..
DOI: 10.1016/j.jaci.2015.12.1342

Tharp M.D. et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of «realworld» evidence. JAMA dermatology. 2019;155(1):29-38. doi: 10.1001/jamadermatol.2018.3447..
DOI: 10.1001/jamadermatol.2018.3447

Marzano A.V., Genovese G., Casazza G., Fierro M.T., Dapavo P., Crimi N., et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. J Eur Acad Dermatol Venereol. 2018;33(5):918-924. doi: 10.1111/jdv.15350..
DOI: 10.1111/jdv.15350

Asero R., Marzano A.V., Ferrucci S., Cugno M. Elevated baseline D-dimer plasma levels are associated with a prompt response to omalizumab in patients with severe CSU. J Allergy Clin Immunol Pract. 2017;5:1740-1742. doi: 10.1016/j.jaip.2017.07.009..
DOI: 10.1016/j.jaip.2017.07.009

Maurer M., Metz M., Brehler R., Hillen U., Jakob T., Mahler V., et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018;141:638- 49. doi: 10.1016/j.jaci.2017.06.032..
DOI: 10.1016/j.jaci.2017.06.032

Gericke J., Metz M., Ohanyan T., Weller K., Altrichter S., Skov P.S., et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;139:1059-61.e1. DOI: 10.1016/j.jaci.2016.07.047.
DOI: 10.1016/j.jaci.2016.07.047

Zuberbier T., Aberer W., Asero R., et al. The EAACI/GA2LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update. Allergy. 2018;73(7):1393-1414. doi: 10.1111/all.13397..
DOI: 10.1111/all.13397

Pawankar R., Mori S., Ozu C., Kimura S. Overview on the pathomechanisms of allergic rhinitis. Asia Pac Allergy. 2011;1:157-67. doi: 10.5415/apallergy.2011.1.3.157..
DOI: 10.5415/apallergy.2011.1.3.157

Phillips K.M., Hoehle L.P., Caradonna D.S., Gray S.T., Sedaghat A.R. Association of severity of chronic rhinosinusitis with degree of comorbid asthma control. Ann Allergy Asthma Immunol. 2016;117:651-654. doi: 10.1016/j.anai.2016.09.439..
DOI: 10.1016/j.anai.2016.09.439

Leynaert B., Neukirch F., Demoly P., Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol. 2000;106:S201-5. doi: 10.1067/mai.2000.110151..
DOI: 10.1067/mai.2000.110151

Asher M.I., Montefort S., Björkstén B., Lai C.K., Strachan D.P., Weiland S.K., et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733-743. doi: 10.1016/s0140-6736(06)69283-0..
DOI: 10.1016/s0140-6736(06)69283-0

Bousquet J., Vignola A.M., Demoly P. Links between rhinitis and asthma. Allergy. 2003;58:691-706. doi: 10.1034/j.1398-9995.2003.00105.x..
DOI: 10.1034/j.1398-9995.2003.00105.x

Simons F.E. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol. 1999;104:534-540. doi: 10.1016/s0091-6749(99)70320-9..
DOI: 10.1016/s0091-6749(99)70320-9

Vignola A.M., Chanez P., Godard P., Bousquet J. Relationships between rhinitis and asthma. Allergy. 1998;53:833-839. doi: 10.1111/j.1398-9995.1998.tb03988.x..
DOI: 10.1111/j.1398-9995.1998.tb03988.x

Ziyab A.H. Prevalence and risk factors of asthma, rhinitis, and eczema and their multimorbidity among young adults in Kuwait: a cross-sectional study. Biomed Res Int. 2017;2017:1-10. doi: 10.1155/2017/2184193..
DOI: 10.1155/2017/2184193

Grossman J. One airway, one disease. Chest. 1997;111:11S-6S. doi: 10.1378/chest.111.2_ supplement.11s..
DOI: 10.1378/chest.111.2_ supplement.11s

Brito Rde C., da Silva G.A., Motta M.E., Brito M.C. The association of rhinoconjunctivitis and asthma symptoms in adolescents. Rev Port Pneumol. 2009;15:613-28. doi: 10.1016/s2173-5115(09)70137-x..
DOI: 10.1016/s2173-5115(09)70137-x

Adelroth E., Rak S., Haahtela T., Aasand G., Rosenhall L., Zetterstrom O., et al. Recombinant humanized mAb-E25, an antiIgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;106:253-259. doi: 10.1067/mai.2000.108310..
DOI: 10.1067/mai.2000.108310

Casale T.B., Condemi J., LaForce C., Nayak A., Rowe M., Watrous M., et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001;286:2956-2967. doi: 10.1001/jama.286.23.2956..
DOI: 10.1001/jama.286.23.2956

Vignola A.M., Humbert M., Bousquet J., Boulet L.P., Hedgecock S., Blogg M., et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59:709- 717. doi: 10.1111/j.1398-9995.2004.00550.x..
DOI: 10.1111/j.1398-9995.2004.00550.x

Tabbara K.F. Ocular complications of vernal keratoconjunctivitis. Can J Ophthalmol. 1999;34:88-92. Available at: https://www. ncbi.nlm.nih.gov/pubmed/10321319.https://www

Tabbara K.F. Ocular complications of vernal keratoconjunctivitis. Can J Ophthalmol. 1999;34:88-92. Available at: https://www. ncbi.nlm.nih.gov/pubmed/10321319.https://www

Vichyanond P., Pacharn P., Pleyer U., Leonardi A. Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes. Pediatr Allergy Immunol. 2014;25:314-22. doi: 10.1111/pai.12197..
DOI: 10.1111/pai.12197

Bonini S., Bonini S., Lambiase A., Marchi S., Pasqualetti P., Zuccaro O., et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with longterm follow-up. Ophthalmology. 2000;107:1157-63. doi: 10.1016/s0161-6420(00)00092-0..
DOI: 10.1016/s0161-6420(00)00092-0

Sánchez J., Cardona R. Omalizumab. An option in vernal keratoconjunctivitis? Allergol Immunopathol (Madr). 2012;40:319-20. doi: 10.1016/j.aller.2011.08.002..
DOI: 10.1016/j.aller.2011.08.002

de Klerk T.A., Sharma V., Arkwright P.D., Biswas S. Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab. J AAPOS. 2013;17:305-6. doi: 10.1016/j.jaapos.2012.12.153..
DOI: 10.1016/j.jaapos.2012.12.153

Doan S., Amat F., Gabison E., Saf S., Cochereau I., Just J. Omalizumab in severe refractory vernal keratoconjunctivitis in children: case series and review of the literature. Ophthalmol Ther. 2017;6:195-206. doi: 10.1007/s40123-016-0074-2..
DOI: 10.1007/s40123-016-0074-2

EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50:1-12. doi: 10.4193/rhino50e2..
DOI: 10.4193/rhino50e2

Bachert C., Zhang L., Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol. 2015;136:1431-1440. doi: 10.1016/j.jaci.2015.10.010..
DOI: 10.1016/j.jaci.2015.10.010

Tomassen P., Vandeplas G., Van Zele T., Cardell L.O., Arebro J., Olze H., et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137:1449-1456.e4. doi: 10.1016/j.jaci.2015.12.1324..
DOI: 10.1016/j.jaci.2015.12.1324

Bantz S.K., Zhu Z., Zheng T. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell Immunol. 2014;5:202. doi: 10.4172/2155- 9899.1000202..
DOI: 10.4172/2155- 9899.1000202

Jarvis D., Newson R., Lotvall J., Hastan D., Tomassen P., Keil T., et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy. 2012;67:91-8. doi: 10.1111/j.1398-9995.2011.02709.x..
DOI: 10.1111/j.1398-9995.2011.02709.x

Bachert C., Gevaert P., Holtappels G., Johansson S.G., van Cauwenberge P. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol. 2001;107:607-614. doi: 10.1067/mai.2001.112374..
DOI: 10.1067/mai.2001.112374

Kang J.W., Nahm D.H., Suh K.S., Kim H.Y., Park H.S. Local production of specific IgE antibody to house dust mite in nasal polyp tissues. J Asthma Allergy Clin Immunol. 1998;18:426-433.

Ying S., Humbert M., Meng Q., Pfister R., Menz G., Gould H.J., et al. Local expression of epsilon germline gene transcripts and RNA for the epsilon heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. J Allergy Clin Immunol. 2001;107:686-692. doi: 10.1067/mai.2001.114339..
DOI: 10.1067/mai.2001.114339

Zhang N., Holtappels G., Gevaert P., Patou J., Dhaliwal B., Gould H., et al. Mucosal tissue polyclonal IgE is functional in response to allergen and SEB. Allergy. 2011;66:141-148. doi: 10.1111/j.1398-9995.2010.02448.x..
DOI: 10.1111/j.1398-9995.2010.02448.x

Van Zele T., Gevaert P., Holtappels G., Beule A., Wormald P.J., Mayr S., et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010;125:1069-1076.e4. doi: 10.1016/j.jaci.2010.02.020..
DOI: 10.1016/j.jaci.2010.02.020

Penn R., Mikula S. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol. 2007;21:428-432. doi: 10.2500/ajr.2007.21.3060..
DOI: 10.2500/ajr.2007.21.3060

Vennera Mdel C., Picado C., Mullol J., Alobid I., Bernal-Sprekelsen M. Efficacy of omalizumab in the treatment of nasal polyps. Thorax. 2011;66:824-825. doi: 10.1136/thx.2010.152835..
DOI: 10.1136/thx.2010.152835

Gevaert P., Calus L., Van Zele T., Blomme K., De Ruyck N., Bauters W., et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131:110-116.e1. doi: 10.1016/j.jaci.2012.07.047..
DOI: 10.1016/j.jaci.2012.07.047

Gevaert P., Calus L., Van Zele T., Blomme K., De Ruyck N., Bauters W., et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131:110-116.e1. doi: 10.1016/j.jaci.2012.07.047..
DOI: 10.1016/j.jaci.2012.07.047

Pinto J.M., Mehta N., DiTineo M., Wang J., Baroody F.M., Naclerio R.M. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010;48:318-324. doi: 10.4193/rhin09.144..
DOI: 10.4193/rhin09.144

Garcia G., Magnan A., Chiron R., et al. A proofof-concept, randomized, controlled trial of omalizumab in patients with severe, difficulttocontrol, nonatopic asthma. Chest. 2013;144(2):411–419. doi: 10.1378/chest.12-1961..
DOI: 10.1378/chest.12-1961

Domingo C., Pomares X., Angril N., Rudi N., Amengual M.J., Mirapeix R.M. Effectiveness of omalizumab in non-allergic severe asthma. J Biol Regul Homeost Agents. 2013;27(1):45–53.

Bousquet J., Lockey R., Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102(4 Pt 1):558– 562. doi: 10.1016/s0091-6749(98)70271-4..
DOI: 10.1016/s0091-6749(98)70271-4

James C., Bernstein D.I. Allergen immunotherapy: an updated review of safety. Curr Opin Allergy Clin Immunol. 2017;17(1):55–59. doi: 10.1097/aci.0000000000000335..
DOI: 10.1097/aci.0000000000000335

Normansell R., Kew K.M., Bridgman A.L. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2015;(8):CD011293. doi: 10.1002/14651858. cd011293.pub2..
DOI: 10.1002/14651858. cd011293.pub2

Lambert N., Guiddir T., Amat F., Just J. Pretreatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma. Pediatr Allergy Immunol. 2014;25(8):829–832. doi: 10.1111/ pai.12306..
DOI: 10.1111/ pai.12306

Casale T.B., Busse W.W., Kline J.N., et al; Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117(1):134–140. doi: 10.1016/j.jaci.2005.09.036..
DOI: 10.1016/j.jaci.2005.09.036

Massanari M., Nelson H., Casale T., et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125(2):383–389. doi: 10.1016/j. jaci.2009.11.022..
DOI: 10.1016/j. jaci.2009.11.022

Dantzer J.A., Wood R.A. The use of omalizumab in allergen immunotherapy. Clin Exp Allergy. 2018;48(3):232–240. doi: 10.1111/ cea.13084..
DOI: 10.1111/ cea.13084

Incorvaia C., Mauro M., Gritti B.L., Makri E., Ridolo E. Venom immunotherapy in patients with allergic reactions to insect stings. Expert Rev Clin Immunol. 2018;14(1):53–59. doi: 10.1080/1744666x.2018.1413350..
DOI: 10.1080/1744666x.2018.1413350

Boni E., Incorvaia C., Mauro M. Dosedependence of protection from systemic reactions to venom immunotherapy by omalizumab. Clin Mol Allergy. 2016;14:14. doi: 10.1186/s12948-016-0051-2..
DOI: 10.1186/s12948-016-0051-2

Abdel-Gadir A., Schneider L., Casini A., et al. Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. Clin Exp Allergy. 2018;48(7):825–836. doi: 10.1111/cea.13161..
DOI: 10.1111/cea.13161

Ильина Н.И., Курбачева О.М., Павлова К.С. Эффективность аллергенспецифической иммунотерапии на фоне приема препарата Омализумаб у пациентов с атопическими заболеваниями. Вопросы современной педиатрии. 2008;7(3):44-51. Режим доступа: https://vsp.spr-journal.ru/jour/article/view/1397.https://vsp.spr-journal.ru/jour/article/view/1397

Ильина Н.И., Курбачева О.М., Павлова К.С. Эффективность аллергенспецифической иммунотерапии на фоне приема препарата Омализумаб у пациентов с атопическими заболеваниями. Вопросы современной педиатрии. 2008;7(3):44-51. Режим доступа: https://vsp.spr-journal.ru/jour/article/view/1397.https://vsp.spr-journal.ru/jour/article/view/1397

Ильина Н.И., Курбачева О.М., Павлова К.С. Возможности комбинированного применения аллерген-специфической иммунотерапии с параллельным введением антиIgE-антител в лечении пациентов с атопическими заболеваниями. Российский аллергологический журнал. 2008;2:17-27. Режим доступа: http://rusalljournal.ru/journal/pdf/2008/2008-2/2-2008.pdf.http://rusalljournal.ru/journal/pdf/2008/2008-2/2-2008.pdf

Ильина Н.И., Курбачева О.М., Павлова К.С. Возможности комбинированного применения аллерген-специфической иммунотерапии с параллельным введением антиIgE-антител в лечении пациентов с атопическими заболеваниями. Российский аллергологический журнал. 2008;2:17-27. Режим доступа: http://rusalljournal.ru/journal/pdf/2008/2008-2/2-2008.pdf.http://rusalljournal.ru/journal/pdf/2008/2008-2/2-2008.pdf

Shah A., Panjabi C. Allergic bronchopulmonary aspergillosis: a perplexing clinical entity. Allergy Asthma Immunol Res. 2016;8:282- 97. doi: 10.4168/aair.2016.8.4.282..
DOI: 10.4168/aair.2016.8.4.282

Agarwal R., Chakrabarti A., Shah A., Gupta D., Meis J.F., Guleria R., et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43:850-873. doi: 10.1111/cea.12141..
DOI: 10.1111/cea.12141

Agarwal R., Aggarwal A.N., Gupta D., Jindal S.K. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2009;13:936-944.

Hoyt A.E., Borish L., Gurrola J., Payne S. Allergic fungal rhinosinusitis. J Allergy Clin Immunol Pract. 2016;4:599-604. doi: 10.1016/j.jaip.2016.03.010..
DOI: 10.1016/j.jaip.2016.03.010

Humbert M., Bousquet J., Bachert C., Palomares O., Pfister P., Kottakis I., Jaumont X., Thomsen S.F., Papadopoulos N.G. IgEMediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. J Allergy Clin Immunol Pract. 2019;7(5):1418- 1429. doi: 10.1016/j.jaip.2019.02.030..
DOI: 10.1016/j.jaip.2019.02.030

Eigenmann P.A., Beyer K., Wesley Burks A., et al. New visions for food allergy: an iPAC summary and future trends. Pediatr Allergy Immunol. 2008;19(19):26-39. doi: 10.1111/j.1399-3038.2008.00765.x..
DOI: 10.1111/j.1399-3038.2008.00765.x

Sicherer S.H. Food allergy. Mt Sinai J Med. 2011;78:683-696. doi: 10.1002/msj.20292..
DOI: 10.1002/msj.20292

Sicherer S.H., Sampson H.A. Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol. 2014;133:291-307; quiz 8. doi: 10.1016/j.jaci.2013.11.020..
DOI: 10.1016/j.jaci.2013.11.020

Tordesillas L., Berin M.C., Sampson H.A. Immunology of food allergy. Immunity. 2017;47:32-50. doi: 10.1016/j.immuni.2017.07.004..
DOI: 10.1016/j.immuni.2017.07.004

Mills E.N., Mackie A.R., Burney P., Beyer K., Frewer L., Madsen C., et al. The prevalence, cost and basis of food allergy across Europe. Allergy. 2007;62:717-722. doi: 10.1111/j.1398-9995.2007.01425.x..
DOI: 10.1111/j.1398-9995.2007.01425.x

Wang J., Liu A.H. Food allergies and asthma. Curr Opin Allergy Clin Immunol. 2011;11:249- 254. doi: 10.1097/aci.0b013e3283464c8e..
DOI: 10.1097/aci.0b013e3283464c8e

Begin P., Chinthrajah R.S., Nadeau K.C. Oral immunotherapy for the treatment of food allergy. Hum Vaccin Immunother. 2014;10:2295-2302. doi: 10.4161/hv.29233..
DOI: 10.4161/hv.29233

Nadeau K.C., Kohli A., Iyengar S., DeKruyff R.H., Umetsu D.T. Oral immunotherapy and anti-IgE antibody-adjunctive treatment for food allergy. Immunol Allergy Clin North Am. 2012;32:111-133. doi: 10.1016/j.iac.2011.11.004..
DOI: 10.1016/j.iac.2011.11.004

Umetsu D.T, Rachid R., Schneider L.C. Oral immunotherapy and anti-IgE antibody treatment for food allergy. World Allergy Organ J. 2015;8:20. doi: 10.1186/s40413-015-0070-3..
DOI: 10.1186/s40413-015-0070-3

Andorf S., Purington N., Block W.M., Long A.J., Tupa D., Brittain E., et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018;3:85-94. doi: 10.1016/s2468-1253(17)30392-8..
DOI: 10.1016/s2468-1253(17)30392-8

Labrosse R., Graham F., Des Roches A., Begin P. The use of omalizumab in food oral immunotherapy. Arch Immunol Ther Exp (Warsz). 2017;65:189-99. doi: 10.1007/s00005-016-0420-z..
DOI: 10.1007/s00005-016-0420-z

Frischmeyer-Guerrerio P.A., Masilamani M., Gu W., Brittain E., Wood R., Kim J., et al. Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2017;140:1043-1053.e8. doi: 10.1016/j.jaci.2017.03.028..
DOI: 10.1016/j.jaci.2017.03.028

Savage J.H., Courneya J.P., Sterba P.M., Macglashan D.W., Saini S.S., Wood R.A. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol. 2012;130:1123-1129.e2. doi: 10.1016/j.jaci.2012.05.039..
DOI: 10.1016/j.jaci.2012.05.039

Rafi A., Do L.T., Katz R., Sheinkopf L.E., Simons C.W., Klaustermeyer W. Effects of omalizumab in patients with food allergy. Allergy Asthma Proc. 2010;31:76-83. doi: 10.2500/aap.2010.31.3304..
DOI: 10.2500/aap.2010.31.3304

Sampson H.A., Leung D.Y., Burks A.W., Lack G., Bahna S.L., Jones S.M., et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127:1309-13010. e1. doi: 10.1016/j.jaci.2011.01.051..
DOI: 10.1016/j.jaci.2011.01.051

Leung D.Y., Sampson H.A., Yunginger J.W., Burks A.W. Jr, Schneider L.C., Wortel C.H., et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348:986- 993. doi: 10.1056/nejmoa022613..
DOI: 10.1056/nejmoa022613

Galli E., Gianni S., Auricchio G., Brunetti E., Mancino G., Rossi P. Atopic dermatitis and asthma. Allergy Asthma Proc. 2007;28:540-3. doi: 10.2500/aap2007.28.3048..
DOI: 10.2500/aap2007.28.3048

Eichenfield L.F., Hanifin J.M., Beck L.A., Lemanske R.F. Jr, Sampson H.A., Weiss S.T., et al. Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics. 2003;111:608-616. doi: 10.1542/peds.111.3.608..
DOI: 10.1542/peds.111.3.608

van der Hulst A.E., Klip H., Brand P.L. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol. 2007;120:565-569. doi: 10.1016/j.jaci.2007.05.042..
DOI: 10.1016/j.jaci.2007.05.042

Celakovská J., Buka C.J. The severity of atopic dermatitis evaluated with the SCORAD index and the occurrence of bronchial asthma and rhinitis, and the duration of atopic dermatitis. Allergy Rhinol (Providence). 2016;7:8-13. doi: 10.2500/ar.2016.7.0144..
DOI: 10.2500/ar.2016.7.0144

Iyengar S.R., Hoyte E.G., Loza A., Bonaccorso S., Chiang D., Umetsu D.T., et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol. 2013;162:89-93. doi: 10.1159/000350486..
DOI: 10.1159/000350486

Heil P.M., Maurer D., Klein B., Hultsch T., Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebocontrolled and double blind pilot study. J Dtsch Dermatol Ges. 2010;8:990-998. DOI: 10.1111/j.1610-0387.2010.07497.x..
DOI: 10.1111/j.1610-0387.2010.07497.x

Holm J.G., Agner T., Sand C., Thomsen S.F. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. Int J Dermatol. 2017;56:18-26. doi: 10.1111/ijd.13353..
DOI: 10.1111/ijd.13353

Chan S., Cornelius V., Chen T., Radulovic S., Wan M., Jahan R., et al. Atopic Dermatitis AntiIgE Paediatric Trial (ADAPT): the role of antiIgE in severe paediatric eczema: study protocol for a randomised controlled trial. Trials. 2017;18:136. doi: 10.1186/s13063-017-1809-7..
DOI: 10.1186/s13063-017-1809-7

Sheinkopf L.E., Rafi A.W., Do L.T., Katz R.M., Klaustermeyer W.B. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc. 2008;29:530-537. doi: 10.2500/aap.2008.29.3160..
DOI: 10.2500/aap.2008.29.3160

Дополнительная информация
Язык текста: Русский
ISSN: 2079-701X
Унифицированный идентификатор ресурса для цитирования: //medj.rucml.ru/journal/4e432d4d4544534f5645542d41525449434c452d323031392d302d31352d302d33382d3439/